CONFERENCE UPDATE : ENDO 2020

Liraglutide is effective in weight management of adolescents with obesity

issue21_website images_CU2_Study1

FINDINGS

  • At week 56, participants who received liraglutide showed significantly reduced body mass index standard deviation score (BMI SDS) and greater improvements in body weight, body mass index (BMI), waist circumference, and other weight-related outcomes compared to those who received placebo
  • At week 56, there were no significant differences in blood pressure, fasting lipids, fasting plasma glucose or hemoglobin A1c (HbA1c)
  • At week 82 (after 26 weeks of drug discontinuation, but continued lifestyle therapy) participants who had received liraglutide during the 56-week treatment period had a greater increase in BMI SDS than those in the placebo group
  • The safety profile of liraglutide was similar to that of adults with no reported unexpected safety concerns or severe hypoglycemia
  • Adolescents taking liraglutide reported more gastrointestinal side effects (64.8%) than those taking placebo (36.5%) with few serious adverse events (3 versus 5 events, respectively)
  • Mental health questionnaire results at week 52 were similar in both groups, and the authors found no apparent effects on growth or pubertal development

"The results of this clinical trial suggested that liraglutide 3.0mg given once daily along with lifestyle therapy improves BMI, BMI SDS, other measures of BMI and body weight among adolescents with obesity who have had difficulties in managing their weight with lifestyle therapy alone"

Get access to our exclusive articles.